1. Home
  2. BWFG vs FULC Comparison

BWFG vs FULC Comparison

Compare BWFG & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bankwell Financial Group Inc.

BWFG

Bankwell Financial Group Inc.

HOLD

Current Price

$62.21

Market Cap

475.4M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.72

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWFG
FULC
Founded
2002
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
475.4M
467.8M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
BWFG
FULC
Price
$62.21
$3.72
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$55.00
$16.38
AVG Volume (30 Days)
81.7K
1.9M
Earning Date
04-22-2026
04-27-2026
Dividend Yield
1.52%
N/A
EPS Growth
261.79
N/A
EPS
1.41
N/A
Revenue
$2,826,000.00
N/A
Revenue This Year
$17.64
N/A
Revenue Next Year
$6.21
N/A
P/E Ratio
$42.96
N/A
Revenue Growth
43.96
N/A
52 Week Low
$38.20
$2.83
52 Week High
$61.86
$15.74

Technical Indicators

Market Signals
Indicator
BWFG
FULC
Relative Strength Index (RSI) 66.73 44.94
Support Level $45.62 $3.41
Resistance Level N/A $4.02
Average True Range (ATR) 1.87 0.18
MACD 0.09 0.09
Stochastic Oscillator 95.77 67.71

Price Performance

Historical Comparison
BWFG
FULC

About BWFG Bankwell Financial Group Inc.

Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: